Background. The low efficacy of rotavirus vaccines in clinical trials performed in low-resource settings may be partially explained by acquired immunity from natural exposure, especially in settings with high disease incidence.
Rotavirus is the most common cause of severe diarrhea in children worldwide and was estimated to be responsible for 122 000 [1] to 215 000 [2] deaths in 2013. The introduction of an effective and safe rotavirus vaccine in 81 countries as of May 2016 [3] has been a major public health success in the last decade and has led to substantial reductions in hospitalization and rotavirus diarrhea-related morbidity [4, 5] . However, in low-and middle-income countries, where disease incidence is highest, oral rotavirus vaccines have been found to be the least effective [6, 7] . Estimates of vaccine efficacy against severe rotavirus diarrhea (RVD) in early trials conducted in Europe and the Americas were >95% [8, 9] . In comparison, estimates in low-resource settings ranged widely from 40% to 85% [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In addition, efficacy decreased over time in some trials, with estimates in the second year of life <30% in sub-Saharan Africa [11, 15] . This latter observation has led to the investigation of strategies to improve efficacy later in childhood, for example with the addition of a booster dose [20] .
While reduced vaccine immunogenicity has been presumed to be the major cause of both low and short-lived vaccine efficacy, the rotavirus incidence rate in the geographic area of the trial may also cause heterogeneity in efficacy estimates. In settings with high incidence, unvaccinated control children are likely to be exposed naturally and acquire partial clinical immunity [21] [22] [23] , such that their immune status approaches that of vaccinated children. These controls subsequently experience a lower rate of rotavirus diarrhea than would be expected in rotavirus-naive controls, which constitutes the majority in control groups in trials in low-incidence settings.
Because vaccine efficacy is usually calculated as a relative measure, efficacies can be estimated as low not only if the vaccinated group experiences more rotavirus diarrhea than expected (suggesting the vaccine is poorly immunogenic), but also if the unvaccinated group is protected and experiences less rotavirus diarrhea than expected. This result is inherent to the mathematical calculation of efficacy, which obscures baseline incidence rates, and may substantially contribute to lower efficacy estimates in low-and middle-income countries. We would expect this phenomenon to have the largest impact on estimates in the second year of life because a large number of children in the control group would be naturally exposed to rotavirus by that time and have some degree of immunity. Therefore, natural immunity may also contribute to the observed waning of efficacy estimates over time. This phenomenon was first described on a theoretical basis for vaccines against infections that confer long-lasting immunity. In this setting, for a vaccine that provides incomplete protection to all individuals (coined a "leaky vaccine" [24] ), vaccine efficacy calculated as (1 -risk ratio) is expected to decrease as follow-up time increases [25, 26] . We extend this work to vaccines against rotavirus, an infection that does not confer long-lasting immunity.
Comparing efficacy estimates across settings without acknowledging the impact of baseline incidence, frequency of natural exposure, and resulting acquired immunity (even if only partial) can lead to misguided conclusions for future public health interventions. Vaccine efficacy estimates from clinical trials are often interpreted as estimates of a biological parameter concerning how well the vaccine prevents disease in individuals, rather than as a population measure that is a function of both biology and statistics. We hypothesize that at least some of the difference in efficacy between high-resource and low-resource settings may be due to the difference in acquired immunity through natural exposure, which is driven by baseline incidence rates. This would suggest that efforts to improve efficacy through biological interventions would not necessarily ameliorate the observed differences in efficacy compared with high-resource settings.
We aimed to assess whether this phenomenon could explain low rotavirus vaccine efficacy estimates in the Performance of Rotavirus and Oral Polio Vaccines in Developing Countries (PROVIDE) study, a randomized controlled trial of monovalent oral rotavirus vaccine in an urban slum of Dhaka, Bangladesh. The study protocol included twice-weekly active diarrheal surveillance that identified even mild rotavirus diarrhea cases, which optimizes the identification of rotavirus diarrhea as a proxy for prior rotavirus exposure. Because the impact of immunity from prior exposure on efficacy estimates should be governed by fixed mathematical relationships between incidence and efficacy, we also simulated trial cohorts under a variety of conditions to understand the relationships between these parameters and the expected variation in vaccine efficacy estimates.
METHODS

PROVIDE
The PROVIDE study was a randomized controlled trial conducted in an urban Mirpur slum in Dhaka, Bangladesh. The study methods have been previously described [19, 27] . In brief, 700 children were enrolled in the first week of life and randomized to receive either monovalent rotavirus vaccine (RV1) at 10 and 17 weeks of age or no RV1. Informed consent was obtained for all participating mothers and infants and the study was registered at ClinicalTrials.gov (NCT01375647) [27] . Field research assistants visited each household twice per week until 2 years of age to identify episodes of diarrhea, defined as ≥3 abnormally loose stools in 24 hours as reported by the mother [27] . Unique episodes were required to be separated by 72 diarrhea-free hours. A stool was collected during each diarrhea episode and tested for rotavirus antigen using the ProSpecT enzyme immunoassay (EIA; Oxoid Ltd, Hampshire, United Kingdom). An episode of RVD was defined by a rotavirus EIA-positive diarrheal stool. Severe RVD was defined by RVD with a Vesikari score of ≥11 [28] . We considered a child to have been naturally exposed and potentially have acquired immunity to rotavirus after they experienced an episode of rotavirus diarrhea, regardless of severity. This classification was used only to distinguish children with rotavirus exposure and the potential for natural immunity from those who were not yet exposed; we did not assign a level of protection to that immunity, such that children could be immune, partially, or not at all protected after their first episode as evidenced by their future experience of RVD.
To incorporate multiple RVD events in the statistical models to estimate efficacy, we used the Andersen and Gill extension of the Cox model for recurrent events [29] to estimate vaccine efficacy as (1 -hazard ratio) × 100. This analysis assumes an unrestricted or common baseline hazard for all events (which can be modified by vaccination and acquisition of natural immunity), and defines risk intervals using a counting process formulation. Using age as the time scale, each subject could contribute multiple risk periods by being censored at each diarrhea episode and having a delayed entry for the risk period of the subsequent episode at 4 days after the previous episode ended (as a new diarrhea episode could not be defined within 72 hours of the previous episode). All children were considered at risk until drop-out or administrative censoring at 2 years of age. Variance estimates were calculated using the robust sandwich estimator to account for correlation between risk periods within each child [30] . Because efficacy changed over time, which indicates that the proportional hazards assumption of the Cox model was not met, the reported efficacies should be interpreted as the average efficacy over the time interval included in that estimate.
We first reestimated the previously published [19] traditional per-protocol efficacy in which the exposure was the randomized assignment and excluded children in the vaccination group who did not receive both doses in the protocol-specified window. To restrict the measured efficacy to rotavirus-naive children, we next estimated a modified per-protocol efficacy that excluded all risk periods in both arms that corresponded to children with prior exposure, defined as a previous RVD episode of any severity. We also estimated the efficacy of natural immunity by comparing risk periods corresponding to children with prior exposure (from both the vaccinated and control groups) to risk periods from rotavirus-naive controls, as there was no difference in immunity between the vaccinated with prior exposure and the unvaccinated with prior exposure (test of homogeneity P = .6). Finally, we estimated the combined efficacy of immunity (from vaccination or prior exposure) compared to rotavirus-naive controls. These analyses were completed for the outcome defined by RVD of any severity and by severe RVD, in both the postvaccination period (18 weeks to 2 years) and separately in the first and second years of life. We calculated the impact of natural immunity on rotavirus vaccine efficacy estimates as the difference in efficacy between the traditional and modified per-protocol estimates.
Simulations
To understand the relationships between rotavirus incidence, expected vaccine efficacy in a rotavirus-naive population, and estimated vaccine efficacies in trial settings, we simulated clinical trial cohorts under a range of assumed incidence rates and vaccine efficacies. Specifically, we simulated birth cohort study populations of 5000 children with complete follow-up, in which 50% were vaccinated. Rotavirus and severe rotavirus diarrhea event times were simulated in a Poisson counting process formulation using exponential distributions parameterized by RVD and severe RVD incidence rates and the assumed true efficacies of immunity against RVD and severe RVD, respectively. Children who experienced a previous RVD episode were classified as previously exposed for all future risk periods, and following event times were simulated using an exponential distribution parameterized by both the incidence rate and efficacy of immunity from natural infection. For simplicity, immunity acquired after vaccination and natural infection were assumed to have equivalent efficacies as this was approximately true in PROVIDE (see Results below). Recurrent event times were simulated until administrative censoring at 2 years of age.
We quantified the impact of prior exposure and natural immunity on efficacy as the difference between the traditional vaccine efficacy estimate by randomization group and the efficacy of vaccination compared to rotavirus-naive controls only. We used the 2.5th and 97.5th percentiles of the effect estimates from 200 simulated cohorts to calculate 95% confidence limits. Incidence rate and efficacy parameters were extracted from a variety of rotavirus vaccine trials published from 24 countries [8-19, 31, 32] as well as a broader range of plausible values. In the simulations parameterized from published trials and the simulated theoretical cohorts, the incidence of RVD of any severity was assumed to be 2.9 times the incidence of severe RVD based on that ratio in the first year of life in PROVIDE (2.9) and a community-based observational birth cohort study, MAL-ED (2.9 across all 8 sites) [33, 34] , which both had twice-weekly active diarrheal surveillance. For the theoretical cohorts, vaccine efficacy against any RVD was assumed to be 15% lower than the efficacy against severe RVD based on the average of that parameter from the included published trials.
RESULTS
PROVIDE
Of 700 children enrolled and randomized in PROVIDE, 678 (96.9%) were included in the per-protocol analysis. There were 92 drop-outs in the first year [19] and 16 drop-outs in the second year, such that 592 (84.6%) enrolled children and 577 (85.1%) children in the per-protocol analysis completed follow-up to 2 years. Reasons for drop-out in the second year were consent withdrawal (n = 4) and mother unreachable for >60 days or until the end of 2-year follow-up (n = 12). Crude Kaplan-Meier curves for the time to first RVD highlight a protective effect of vaccination that starts after administration of the second RV1 dose (Figure 1 ). Without considering prior exposure, the vaccine efficacy against severe RVD in the first year of life postvaccination (18 [19] .
Excluding risk periods in which children had prior exposure to appropriately compare rotavirus-naive vaccinated and controls, the estimated efficacy of RV1 against severe RVD in the postvaccination period was 70.2% (95% CI, 44.5%-84.0%). The difference between this and the traditional estimate quantifies the impact of baseline incidence and acquired immunity on efficacy, such that the estimate underestimated the expected efficacy in a rotavirus-naive population by 7.1% (Table 1) . A slightly lower difference in estimates was observed for RVD of any severity. Strikingly, vaccine efficacy estimates against severe RVD in the second year of life were most affected, underestimating the vaccine efficacy that would be estimated in a Table 1 ).
The efficacy of natural immunity against severe RVD in the postvaccination period was 80.5% (95% CI, 42.3%-93.4%) in a comparison of children with prior exposure to rotavirus-naive controls. This estimate was 10.3% higher than the efficacy estimate for vaccination (comparing rotavirus-naive vaccinated vs rotavirus-naive controls). No children with prior exposure had a severe diarrhea episode in the second year of life (efficacy of 100%), compared to a corresponding vaccine efficacy of 45.7% (95% CI, -93.4% to 84.7%) in the rotavirus-naive ( Table 1 ). The Kaplan-Meier curve for time to first severe rotavirus diarrhea episode, stratified into 3 time-varying exposure groups-vaccinated and rotavirus-naive, unvaccinated and rotavirus-naive, and previously exposed (from both the RV1 and no RV1 arms)-shows protection both from vaccination and prior exposure ( Figure 2) . Overall, the combined efficacy of immunity (from vaccination or prior exposure) compared to rotavirus-naive controls against severe RVD in the postvaccination period was 74.8% (95% CI, 54.5%-86.1%).
Simulations
Using RVD incidence rates and vaccine efficacies from published rotavirus vaccine trials as parameters in the simulated cohorts, we estimated potential variation in year 2 efficacy estimates against severe RVD due to natural immunity up to nearly 20% (Table 2 ). In high-resource settings where efficacy was high [8, 9] , this expected variation was relatively low, between 0 and 3% in year 2. The variation in estimates in a simulation with parameters from PROVIDE was similar to that based on the raw data estimated above (13.5% difference in year 2 estimate with raw data vs 15.5% [95% CI, 8.5%-24.1%] difference in simulation; Table 2) .
At a fixed level of vaccine efficacy, the amount of expected variation in vaccine efficacy estimates increased linearly with RVD incidence rate and at a faster rate for lower vaccine efficacies ( Figure 3A ). For example, variation in observed efficacy estimates at a plausible vaccine efficacy of 50% and severe RVD incidence rate of 10 cases per 100 person-years was 14.6% (95% CI, 4.1%-25.6%) in year 2. Conversely, at a fixed RVD incidence rate, the expected variation in vaccine efficacy estimates was nonlinear and peaked at an efficacy in a rotavirus-naive Extended Kaplan-Meier curves [41] for time to first severe rotavirus diarrhea episode in the per-protocol population (n = 678) of the Performance of Rotavirus and Oral Polio Vaccines in Developing Countries (PROVIDE) study in Dhaka, Bangladesh, in which children become previously exposed at the time of their first rotavirus diarrhea episode of any severity. At the end of follow-up, 249 children were vaccinated and rotavirus-naive, 244 children were unvaccinated and rotavirus-naive, and 185 children from both the monovalent rotavirus vaccine (RV1) and no RV1 arms had been previously exposed (potential for natural immunity). a Per-protocol vaccine efficacy compares all vaccinated to unvaccinated children; per-protocol vaccine efficacy in the rotavirus-naive excludes all children from both arms with prior exposure; efficacy of natural immunity compares children with prior exposure (vaccinated or control) to unvaccinated rotavirus-naive children; efficacy of any immunity compares children with immunity (from vaccination or prior exposure) to unvaccinated rotavirus-naive children.
Table 1. Per-Protocol Estimates of the Efficacy of Rotavirus Vaccination and Natural Immunity Against All Rotavirus Diarrhea (RVD) and Severe RVD in the First 2 Years of Life in the Performance of Rotavirus and Oral Polio Vaccines in Developing Countries (PROVIDE) Study
b Difference between traditional vaccine efficacy estimate (column 2) and expected vaccine efficacy in a rotavirus-naive population (column 3).
c Postvaccination period is from 18 weeks to 2 years.
population of slightly higher than 50% ( Figure 3B ). No difference in efficacy estimates would be expected at efficacies of 0 and 100% or at an incidence rate of 0 cases per 100 person-years.
DISCUSSION
This analysis provides the first quantitative assessment of the impact of local rotavirus incidence on rotavirus vaccine efficacy estimates from published clinical trials. We demonstrate substantial effect modification due to acquired immunity in high-incidence settings that results in predictably lower estimates than those observed in low-incidence settings. In PROVIDE, the traditional approach to calculating vaccine efficacy underestimates efficacy against severe rotavirus diarrhea in year 2 in a rotavirus-naive population by 14%. In simulations, we estimate this potential impact on estimates from published rotavirus vaccine trials [8-19, 31, 32] and showed that the expected amount of underestimation increases linearly with the baseline incidence rate and will be greatest for efficacies near 50%. Therefore, this mathematical phenomenon likely explains some but not all of the observed difference in vaccine efficacy between low-and high-resource settings, especially in the second year of life, during which the impact of natural exposure is expected to be greatest. Importantly, the reduction in efficacy estimates introduced by high baseline incidence only becomes relevant at lower vaccine efficacies; we predicted only 0-3% underestimation in the early trials from Europe and the Americas with an efficacy estimated at >95% [8, 9] . Furthermore, the incidence of rotavirus in the vaccinated group remained relatively high in the first year of PROVIDE, at 4.0 cases of severe RVD per 100 person-years. Thus, understanding the precipitating reasons for poor vaccine performance in low-resource settings remains critical. Similarly, this phenomenon likely explains some, but not all, of the observed reduction in rotavirus vaccine efficacy over time, which has been attributed to waning immunity. We suggest that high baseline rotavirus incidence should be considered as one of many potential reasons why rotavirus vaccine efficacy is observed to be low in low-resource settings. a Cases per 100 person-years; RVD of any severity incidence rate assumed to be 2.9 times the severe RVD incidence rate based on active surveillance in PROVIDE and MAL-ED [33] .
b Difference between traditional vaccine efficacy estimate and expected vaccine efficacy in a rotavirus-naive population.
c Reported efficacies based on risk of 1 or more rotavirus diarrhea episodes.
d Belgium, Costa Rica, Finland, Germany, Guatemala, Italy, Jamaica, Mexico, Puerto Rico, Sweden, Taiwan, and United States.
e High and low efficacy defined as efficacy of >80% and <80%, respectively, against severe RVD in year 1; high and low incidence defined as severe RVD incidence rate of >5 and <5 cases per 100 person-years, respectively, in year 1.
f Incidence rate and efficacy estimates for this trial are available for year 1 and year 2 combined only [31] .
g Reported efficacies based on incidence rates of RVD.
h Czech Republic, Finland, France, Germany, Italy, and Spain.
i Efficacy estimate against severe RVD in year 2 for this trial is the combined estimate for year 1 and year 2 (year 2 estimate not available) [18] .
j Efficacy estimate against any RVD in year 1 for this trial is the combined estimate for year 1 and year 2 (year 1 estimate not available) [32] .
k Incidence rate and efficacy against any RVD estimates for this trial are for year 2 due to systematic underascertainment of cases in year 1 [13] .
Critically though, it is important to understand this source of variation in efficacy estimates because it highlights that we will not be able explain poor rotavirus vaccine performance (as measured by efficacy in clinical trials) entirely by poor immunogenicity, and naturally acquired immunity may confound the assessment of efforts to improve vaccine performance, especially to counteract apparent waning immunity. In this context, it is difficult to distinguish true waning immunity from decreases in efficacy over time that are expected for a leaky vaccine [35] . This distinction may be even more difficult in a post-vaccine introduction setting, in which we would expect the impact of natural immunity to lessen as reductions in incidence due to indirect protection (herd immunity) occur. In the trial setting, however, we suggest that estimating efficacy in the rotavirus-naive population by excluding risk periods for children who were previously exposed can indicate the magnitude of the impact of natural immunity.
We expect that this type of effect modification is not isolated to rotavirus vaccine trials and likely affects efficacy estimates for vaccines against other diseases that do not confer complete long-lasting immunity as well. Because individuals in this setting are still at risk and included in person-time denominators of incidence rates after they are infected, efficacy calculated as (1 -incidence rate ratio) or (1 -hazard ratio) will be expected to decrease over time. This extends previous work which showed that only the (1 -risk ratio) would be expected to decrease over time for vaccines against infections that confer long-lasting immunity [25, 26] . The RTS,S vaccine against malaria, another infection that does not confer complete immunity, is a second example where this phenomenon may be occurring. The trials of the RTS,S vaccine were disappointing due to low initial estimates of efficacy (<50%) with further waning immunity [36, 37] . Because malaria incidence was relatively high in the areas where these trials were conducted, it is plausible that efficacy estimates are susceptible to the same impact of partial acquired immunity. RTS,S vaccine efficacy was estimated to be lower and with more extreme waning immunity in areas with a high malaria exposure Expected difference in severe rotavirus vaccine estimates from the expected efficacy in a rotavirus-naive population due to acquisition of natural immunity at varying severe rotavirus diarrhea incidence rates and vaccine efficacies in simulated trials. A, Expected difference at high (90%) and low (50%) vaccine efficacy for a range of severe rotavirus diarrhea incidence rates. B, Expected difference at high (15 cases/100 child-years) and low (5 cases/100 child-years) severe rotavirus incidence rates for a range of severe rotavirus vaccine efficacies. For each, the left graph corresponds to overall impact across year 1 and 2, the center graph corresponds to impact in year 1, and the right graph corresponds to impact in year 2.
index compared to areas with a low malaria exposure index in a trial in Kenya with a 7-year-long follow-up period [38, 39] .
Another mathematical explanation has been proposed to suggest that heterogeneity in individual disease risk could cause selection bias to result in reduced vaccine efficacy in settings with higher incidence [40] . This explanation may complement our described phenomenon and further contribute to reduced vaccine efficacy. These researchers suggest that a vaccine efficacy definition that represents a measure of efficacy per unit of exposure would be independent of incidence and therefore more useful for comparison across settings [40] .
This study was limited by the use of previous RVD as a proxy for prior exposure and potential acquisition of natural immunity. However, PROVIDE had the ideal study design to capture prior exposure by previous episodes since active diarrhea surveillance for any severity was conducted twice per week, and we likely captured all symptomatic rotavirus episodes. Because subclinical exposure can occur, in the absence of serology measurements, this definition provides a conservative estimate of the potential acquisition of natural immunity, and our results may underestimate the true expected impact on efficacy estimates. While the PROVIDE data were also limited by few severe RVD episodes in the second year of life resulting in imprecise efficacy estimates, the inclusion of simulated data sets demonstrated that the phenomenon is reproducible with larger sample sizes and under a variety of parameterizations.
A better understanding of the biological causes for reduced rotavirus vaccine efficacy in low-resource settings is needed to maximize the impact of rotavirus vaccines in the populations that are at highest risk for rotavirus morbidity and mortality. However, it is also important to acknowledge that estimates of vaccine efficacy can be lower than those in high-income countries due to frequent exposure and acquired natural immunity in the control group in these settings. This phenomenon should be considered when evaluating the impact of rotavirus vaccines and when proposing modifications to vaccines and their delivery to improve immunogenicity, such as introducing a booster dose to counteract waning immunity. Quantifying the expected variation in vaccine efficacy estimates due to natural exposure helps to improve the interpretation of results from vaccine trials and more accurately identifies the public health impact of vaccines in low-resource settings. 
